A global immune deficit in alzheimer's disease and mild cognitive impairment disclosed by a novel data mining process

Journal of Alzheimer's Disease

Volumn 43, Issue 4, 2014, Pages 1199-1213

  Gironi, Maira ^a,b   Borgiani, Bruno ^a,b   Farina, Elisabetta ^c   Mariani, Enrica ^a   Cursano, Cristina ^a   Alberoni, Margherita ^c   Nemni, Raffaello ^c   Comi, Giancarlo ^b   Buscema, Massimo ^d,e  

^a CAM   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d Semeion centro ricerche di scienze della communicazione   (Italy)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Artificial neural network; machine learning; neurodegeneration; oxidative stress; pattern recognition; relationships

Indexed keywords

ANTIOXIDANT; GLUTATHIONE; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; UBIDECARENONE;

ADAPTIVE IMMUNITY; AGED; ALZHEIMER DISEASE; ARTICLE; ARTIFICIAL NEURAL NETWORK; DATA MINING; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; PATTERN RECOGNITION; ALGORITHM; CLASSIFICATION; FEMALE; IMMUNOLOGY; MALE; PHYSIOLOGY;

AGED; ALGORITHMS; ALZHEIMER DISEASE; DATA MINING; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEURAL NETWORKS (COMPUTER); OXIDATIVE STRESS;

EID: 84919929885     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141116     Document Type: Article

References (82)

1. Gao H, Hong J (2008) Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol 29, 357-365.
2. Färber K, Kettenmann H (2005) Physiology of microglial cells. Brain Res Brain Res Rev 48, 133-143.
3. Block MLHJ (2005) Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 76, 77-98.
4. Newman T,Woolley S, Hughes P, Sibson N, AnthonyD, Perry V (2001) T-cell-and macrophage-mediated axon damage in the absence of a CNS-specific immune response: Involvement of metalloproteinases. Brain 124, 2203-2214.
5. Rich J, Rasmusson D, Folstein M, Carson K, Kawas C, Brandt J (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51-55.
6. Zhao W, Xie W, Xiao Q, Beers D, Appel S (2006) Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem 99, 1176-1187.
7. Kipnis J, Yoles E, Schori H, Hauben E, Shaked I, SchwartzM (2001) Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J Neurosci 21, 4564-4571.
8. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, Kuchroo V, Cohen IR,Weiner H, Schwartz M (2001) Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 21, 3740-3748.
9. Avidan H, Kipnis J, Butovsky O, Caspi R, Schwartz M (2004) Vaccination with autoantigen protects against aggregated beta-amyloid and glutamate toxicity by controlling microglia: Effect of CD4+CD25+ T cells. Eur J Immunol 34, 3434-3445.
10. (2008) Anti-inflammatory drugs fall short in Alzheimer's disease. Nat Med 14, 916.
11. Shechter R, Schwartz M (2013) Harnessing monocytederived macrophages to control central nervous system pathologies: No longer "if" but "how". J Pathol 229, 332-346.
12. Gironi M, Bianchi A, Russo A, Alberon M, Ceresa L, Angelini A, Cursano C, Mariani E, Nemni R, Kullmann C, Farina E, Martinelli Boneschi F (2011) Oxidative imbalance in different neurodegenerative diseases with memory impairment. Neurodegener Dis 8, 129-137.
13. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE,Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
14. Petersen R, Doody R, Kurz A, Mohs R, Morris J, Rabins P, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992.
15. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann PWI (2009) The WEKA data mining software: An update. SIGKDD Explor 11, 10-18.
16. Livingston F (2005) Implementing BreimanTM s Random Forest Algorithm intoWeka-ECE591Q. In Machine Learning Conference Papers.
17. Aha D, Kibler D (1991) Instance-based learning algorithms. In Machine Learning, pp. 37-66.
18. George H, Langley P (1995) Estimating continuous distributions in Bayesian classifiers. In Eleventh Conference on Uncertainty in Artificial Intelligence, San Mateo, pp. 338-345.
19. Collobert R, Bengio S (2004) Links between Perceptrons, MLPs and SVMs. In Proc Int'l Conf on Machine Learning (ICML), pp. 1-8.
20. Quinlan JR (1993) C4.5: Programs for Machine Learning. Morgan Kaufmann Publishers.
21. Buscema M, Breda M, Lodwick W (2013) Training With Input Selection and Testing (TWIST) algorithm: A significant advance in pattern recognition performance of machine learning. J Intell Learn Syst Appl 5, 29-38.
22. BuscemaM(2004) Genetic doping algorithm (GenD): Theory and application. Expert Syst 21, 63-79.
23. Coppedè F, Grossi E, Migheli FML (2010) Polymorphisms in folate-metabolizing genes, chromosome damage, and risk of Down syndrome in Italian women: Identification of key factors using artificial neural networks. BMC Med Genomics 3, 42.
24. Penco S, Grossi E, Cheng S, Intraligi M, Maurelli G (2005) Assessment of the role of genetic polymorphism in venous thrombosis through artificial neural networks. AnnHumGenet 69 (Pt 6), 693-706.
25. Grossi E, Mancini A, Buscema M (2007) International experience on the use of artificial neural networks in gastroenterology. Dig Liver Dis 39, 278-285.
26. Buscema M, Grossi E, Intraligi M, Garbagna N, Andriulli A (2005) An optimized experimental protocol based on neuroevolutionary algorithms. Application to the classification of dyspeptic patients and to the prediction of the effectiveness of their treatment. Artif Intell Med 34, 279-305.
27. Lahner E, Intraligi M, Buscema M, Centanni M, Vannella L (2008) Artificial neural networks in the recognition of the presence of thyroid disease in patients with atrophic body gastritis. World J Gastroenterol 14, 563-568.
28. Buri L, Hassan C, Bersani G, AntiM,BiancoM(2010) Appropriateness guidelines and predictive rules to select patients for upper endoscopy: A nationwide multicenter study. Am J Gastroenterol 105, 1327-1337.
29. Street M, Grossi E,Volta C, Faleschini E, Bernasconi S (2008) Placental determinants of fetal growth: Identification of key factors in the insulin-like growth factor and cytokine systems using artificial neural networks. BMC Pediatr 8, 24.
30. Buscema M, Grossi E, Capriotti M, Babiloni C, Rossini P (2010) The IFAST model allows the prediction of conversion to Alzheimer disease in patients with mild cognitive impairment with high degree of accuracy. Curr Alzheimer Res 7, 173-187.
31. Rotondano G, Cipolletta L, Grossi E, Koch M, Intraligi M (2011) Artificial neural networks accurately predict mortality in patients with non variceal upper GI bleeding. Gastrointest Endosc 73, 218-226.
32. Pace F, Riegler G, de Leone A, Pace M, Cestari R (2010) Is it possible to clinically differentiate erosive from non erosive reflux disease patients? A study using an artificial neural networks-assisted algorithm. Eur J Gastroenterol Hepatol 22, 1163-1168.
33. Buscema M, Grossi E (2008) The semantic connectivity map: An adapting self organising knowledge discovery method in data bases. Experience in gastro-oesophageal reflux disease. Int J Data Min Bioinform 2, 362-404.
34. Buscema M, Grossi E, Snowdon D, Antuono P (2008) Autocontractive maps: An artificial adaptive system for data mining. An application to Alzheimer disease. Curr Alzheimer Res 5, 481-498.
35. Gironi M, Saresella M, Rovaris M, Vaghi M, Nemni R (2013) A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. Immun Ageing 10, 1.
36. Buscema M, Consonni V, Ballabio D, Mauri A, Massini G, Breda M, Todeschini R (2014) K-CM: A new artificial neural network. Application to supervised pattern recognition. Chemom Intell Lab Syst 138, 110-119.
37. Wang I, Su M, Wan I (2011) An essential role of the transcription factor GATA-3 for the function of regulatory T cells yunqi. Immunity 35, 337-348.
38. Selkoe D (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
39. Togo T, Akiyama H, Iseki E, Kondo H, Ikeda K, Kato M, Oda T, Tsuchiya K, Kosaka K (2002) Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 124, 83-92.
40. Quintanilla R, Orellana J, von Bernhardi R (2012) Understanding risk factors for Alzheimer's disease: Interplay of neuroinflammation, connexin-based communication and oxidative stress. Arch Med Res 43, 632-644.
41. Wilcock DM, Griffin WS (2013) Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation 10, 84.
42. Floden AM, Combs CK (2006) Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci 26, 4644-4648.
43. Bellucci A,Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG (2004) Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 165, 1643-1652.
44. Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K (1992) Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 267, 1821-1827.
45. Weitz TM, Town T (2012) Microglia in Alzheimer's disease: It's all about context. Int J Alzheimers Dis 2012, 314185.
46. Licastro F, Porcellini E, Forti P, Buscema M, Carbone I, Ravaglia G, Grossi E (2010) Multi factorial interactions in the pathogenesis pathway of Alzheimer's disease: A new risk charts for prevention of dementia. Immun Ageing 7 (Suppl 1), S4.
47. Grossi E, Buscema MP, Snowdon D, Antuono P (2007) Neuropathological findings processed by artificial neural networks (ANNs) can perfectly distinguish Alzheimer's patients from controls in the Nun Study. BMC Neurol 7, 15.
48. Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Alberoni M, Nemni R, ClericiM(2011) Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer's disease. Brain Behav Immun 25, 539-547.
49. Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sanvito L, Longhi R, Ferrante P (2007) Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol Aging 28, 1163-1169.
50. Town T, Nikolic V, Tan J (2005) The microglial "activation" continuum: From innate to adaptive responses. J Neuroinflammation 2, 24.
51. Rezai-Zadeh K, Gate D, Town T (2009) CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 4, 462-475.
52. Allan S, Tyrrell P, Rothwell N (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5, 629-640.
53. Saresella M, Marventano I, Calabrese E, Piancone F, Rainone V, Gatti A, Alberoni M, Nemni R, Clerici M (2014) A complex proinflammatory role for peripheral monocytes in Alzheimer's disease. J Alzheimers Dis 38, 403-413.
54. Binder C, Chang M, Shaw P, Miller Y, Hartvigsen K, Dewan A,Witztum J (2002) Innate and acquired immunity in atherogenesis. Nat Med 8, 1218-1226.
55. Chou M, Fogelstrand L, Hartvigsen K, Hansen LF, Woelkers D, Shaw PX, Choi J, Perkmann T, Bäckhed F, Miller YI, Hörkkö S, Corr M, Witztum JL, Binder CJ (2009) Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 119, 1335-1349.
56. Shaw PX, Hörkkö S, Chang M, Curtiss LK, Palinski W, Silverman GJ, Witztum JL (2000) Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 105, 1731-1740.
57. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, EmotoM,KawagishiT, MoriiH(2000) Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 148, 171-177.
58. Sjöberg B, Su J, Dahlbom I, Grönlund H,Wikström M, Hedblad B, Berglund G, de Faire U, Frostegard J (2009) Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 203, 528-532.
59. Glass C, Witztum J (2001) Atherosclerosis. The road ahead. Cell 104, 503-516.
60. Van Leeuwen M, Kemna MJ, deWinther MPJ, Boon L, Duijvestijn AM, Henatsch D, Bos N, Gijbels a, Tervaert MJJ, JWC (2013) Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptordeficient mice. PLoS One 8, 1-12.
61. Masztalewicz M, Nowacki P, Kotliega D, Bajer-Czajkowska A, Drechsler H (2014) Anti-oxLDL antibodies are clinically insignificant for stroke patients. Neurol Res 36, 86-91.
62. Gelosa G, Brooks D (2012) The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging 39, 1207-1219.
63. Wirth M, Villeneuve S, Haase C, Madison C, Oh H, Landau S, Rabinovici G, Jagust W (2013) Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70, 1512-1519.
64. Davies LC, Jenkins S, Allen J, Taylor P (2013) Tissue-resident macrophages. Nat Immunol 14, 986-995.
65. Sica A, MantovaniA(2012) Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 122, 787-795.
66. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25, 677-686.
67. Martinez F, Helming L, Gordon S (2009) Alternative activation of macrophages:Animmunologic functional perspective. Annu Rev Immunol 27, 451-483.
68. Biswas S, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11, 889-896.
69. Saresella M, RainoneV, Al-Daghri N, Clerici M, TrabattoniD (2012) The PD-1/PD-L1 pathway in human pathology. Curr Mol Med 12, 259-267.
70. Lucin K, Wyss-Coray T (2010) Immune activation in brain aging and neurodegeneration: Too much or too little? Neuron 64, 110-122.
71. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky A, Graves M, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, BernardG(2005) Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 7, 221-232.
72. Selkoe D (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
73. Villemagne V, Rowe C (2001) Amyloid imaging. Int Psychogeriatr 13(Suppl 2), 41-49.
74. Kantarci K (2013) Proton MRS in mild cognitive impairment. J Magn Reson Imaging 37, 770-777.
75. Radanovic M, Pereira F, Stella F, Aprahamian I, Ferreira L, Forlenza O, Busatto G (2013) White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: A critical review of MRI studies. Expert Rev Neurother 13, 483-493.
76. Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A (2010) Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp Gerontol 45, 53-56.
77. Evin G, Li Q-X (2012) Platelets and Alzheimer's disease: Potential of APP as a biomarker. World J Psychiatry 2, 102-113.
78. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, Tan J (2008) Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 5.
79. Breunig JJ, Guillot-Sestier M-V, Town T (2013) Brain injury, neuroinflammation and Alzheimer's disease. Front Aging Neurosci 5, 51.
80. Rothwell N (2003) Interleukin-1 and neuronal injury: Mechanisms, modification, and therapeutic potential. Brain Behav Immun 17, 152-157.
81. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B (2004) How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: The role of microglia and astrocytes. Aging Cell 3, 169-176.
82. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Fiebich BL, Finch CE, Frautschy S, Griffin WST, Hull M, Landreth G, Lue LF, Mrak R, Mackenzie IR, Mcgeer L, Banion MKO, Pachter J, Pasinetti G, Salaman CP, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Muiswinkel FL Van, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Coray TW (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.